Exact Sciences, colorectal cancer
ESMO: Exact Sciences shows off early colorectal cancer blood test data
As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical data showing its blood-based test can help spot growing tumors | Presented at the annual meeting of the European Society for Medical Oncology,
Cologuard has gone bilingual. The popular mail-in colorectal cancer screening test from Exact Sciences has a new ...
Hosted on MSN1mon
Exact Sciences (EXAS) Rides on Cologuard Sales, New LaunchesExact Sciences EXAS continues to make significant progress with its Cologuard test and efforts to expand Oncotype DX overseas. Advancements in the key pipeline programs are highly promising.
Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue ...
Exact Sciences Corporation’s EXAS robust efforts to enhance Cologuard’s growth are poised to help it grow in the upcoming quarters. The company aims to introduce novel solutions that will ...
Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard through screening programs. Exact Sciences (EXAS) ...
Exact Sciences (EXAS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Mark ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback